Navigation Links
CureHIV Reaches Out to Bill and Melinda Gates to Fund LiSAVIOR
Date:3/28/2008

HILTON HEAD ISLAND, S.C., March 28 /PRNewswire/ -- Dr. Roger Kenneth Hershline PhD MD, the CEO of Global Humanceuticals, Inc. and founder and chairman of the not-for-profit public charity CureHIV.us, announces today that he is reaching out to Bill and Melinda Gates for funding from their Grand Challenges in Global Health initiative. The monies will be used to begin clinical studies of a new drug and treatment method, LiSAVIOR.

This unique new drug is also known as compound NIAID #11039 and has received a patent from the United States with patent number: 6,821,958 on November 23, 2004. Also, the World International Patent Organization published the International Application Number as PCT/US2005/039528 on November 5, 2006.

Dr. Hershline hosted Session V at the World Aids Day Conference China from December 1 to December 3, 2006, to initially present LiSAVIOR.

The proposed roadblock to cure HIV is that current drug and vaccination treatments do not treat the growth of HIV in the gastrointestinal tract. HIV virus multiplies and mutates in the gastrointestinal tract and then is reabsorbed into the blood. This process is known to occur when HIV infection results from the use of contaminated needles or during sexual intercourse. The gastrointestinal tract is comprised of the mouth and its structures, the pharynx, the esophagus, the stomach, the small intestines, the large intestines and the anus.

The proposed solution to overcome this roadblock is the oral clinical use of LiSAVIOR, a drug that is an early stage HIV life cycle inhibitor. LiSAVIOR blocks not only viral entry into cells but also cell-to-cell transfer of the virus. LiSAVIOR is proposed to be used alone or with any known HIV drug and vaccine therapy.

Pre-clinical efficacy testing of LiSAVIOR has shown that the effective concentration of LiSAVIOR is found to be equivalent to diluting a 1% solution of LiSAVIOR one million times. LiSAVIOR is a dry, palatable, non-toxic powder that is stable at room temperature and humidity.

"I am thinking in terms of problem solving. Traditional commercial drug design and projects funding from the NIH has completely ignored this approach to date," stated Dr. Hershline. "I think we have to talk in terms of a cure for HIV. I want to cure HIV and that is why my foundation is called CureHIV.us," concluded Dr. Hershline.

Dr. Hershline is hopeful that Bill and Melinda Gates and their Global Initiative funding looks into the work and progress that he has made towards solving this problem and fills the gap in funding.

Dr. Hershline has a doctorate degree in drug design and a medical degree. Pre-clinical development of LiSAVIOR has been twenty years in the making. Despite the critical need for such a unique and potentially life saving invention, LiSAVIOR remains completely un-funded.

Interested parties can contact Dr. Roger Kenneth Hershline PhD MD thru CureHIV.us Headquarters by email: Roger@CureHIV.us, mail P.O. Box 23467, Hilton Head Is., SC, 29925, by fax: +1-843-342-5924, phone: +1-843-342-5900. Direct to Dr. Hershline: +1-843-683-3683.

Web site: http://www.curehiv.us


'/>"/>
SOURCE CureHIV.us
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
2. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
3. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
4. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
5. Gates Foundation Seeks Proposals for Innovative Global Health Research
6. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
7. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
8. Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... While it’s ... poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , ... medication in darkness or restricted lighting. As such, it eliminates the need to turn ...
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
Breaking Medicine News(10 mins):